Payload Information
General Information of This Payload
| Payload ID | PAY0VJUYY |
|||||
|---|---|---|---|---|---|---|
| Name | Nostocyclopeptide-2 |
|||||
| Synonyms |
Nostocyclopeptide-2
Click to Show/Hide
|
|||||
| Structure |
|
|||||
| Formula | C41H56ClN5O7 |
|||||
| Isosmiles | C[C@H]([C@@H]1[C@H](O1)C2=CC=C(CN3CCNCC3)C=C2)[C@@H](OC([C@@H](NC(C(C)(C)CN4)=O)CC(C)C)=O)C/C=C/C(N[C@@H](C4=O)CC5=CC=C(OC)C(Cl)=C5)=O |
|||||
| InChI |
InChI=1S/C41H56ClN5O7/c1-25(2)20-32-39(50)53-33(26(3)36-37(54-36)29-13-10-27(11-14-29)23-47-18-16-43-17-19-47)8-7-9-35(48)45-31(22-28-12-15-34(52-6)30(42)21-28)38(49)44-24-41(4,5)40(51)46-32/h7,9-15,21,25-26,31-33,36-37,43H,8,16-20,22-24H2,1-6H3,(H,44,49)(H,45,48)(H,46,51)/t26-,31+,32-,33-,36+,37+/m0/s1
|
|||||
| InChIKey |
WPVNVUTUYULLMT-WIOOTYARSA-N
|
|||||
| Pharmaceutical Properties | Molecule Weight |
766.38 |
Polar area |
150.63 |
||
Complexity |
1599.484695 |
xlogp Value |
4.1023 |
|||
Heavy Count |
54 |
Rot Bonds |
10 |
|||
Hbond acc |
9 |
Hbond Donor |
4 |
|||
Each Antibody-drug Conjugate Related to This Payload
Full Information of The Activity Data of The ADC(s) Related to This Payload
MORAb-003 ADC4 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
3-100 nM
|
High FRA expression (FRA +++) | ||
| Method Description |
Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
|
||||
| In Vitro Model | Osteosarcoma | SJSA-1 cells | CVCL_1697 | ||
MORAb-003 ADC2 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
4.7 nM
|
High FRA expression (FRA +++) | ||
| Method Description |
Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
|
||||
| In Vitro Model | Osteosarcoma | SJSA-1 cells | CVCL_1697 | ||
MORAb-003 ADC3 [Investigative]
Revealed Based on the Cell Line Data
| Experiment 1 Reporting the Activity Date of This ADC | [1] | ||||
| Efficacy Data | Half Maximal inhibitory Concentration (lC50) |
12.7 nM
|
High FRA expression (FRA +++) | ||
| Method Description |
Use crystal violet analysis to evaluate the in vitro efficacy of the prepared ADCs. Initially screen all MORAb003 ADCs on IGROV1 (FRi (+++)) and SJSA - 1 (FReg (-)) cells.
|
||||
| In Vitro Model | Osteosarcoma | SJSA-1 cells | CVCL_1697 | ||